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Berna Nakanwagi30, Andrigo B De Nardi8, Winifred Neunzig5, Sally J Nixon31,
Marsden M Onsare32, Antonio Ortega-Pacheco33, Maria C Peleteiro34,
Ruth J Pye31, John F Reece35, Jose Rojas Gutierrez36, Haleema Sadia37,
Sheila K Schmeling38, Olga Shamanova39, Richard K Ssuna40,
Audrey E Steenland-Smit6, Alla Svitich41, Ismail Thoya Ngoka42,
Bogdan A Vit
;
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Abstract Canine transmissible venereal tumour (CTVT) is a clonally transmissible cancer that
originated approximately 11,000 years ago and affects dogs worldwide. Despite the clonal origin of
the CTVT nuclear genome, CTVT mitochondrial genomes (mtDNAs) have been acquired by periodic
capture from transient hosts. We sequenced 449 complete mtDNAs from a global population of
CTVTs, and show that mtDNA horizontal transfer has occurred at least five times, delineating five
tumour clades whose distributions track two millennia of dog global migration. Negative selection
has operated to prevent accumulation of deleterious mutations in captured mtDNA, and
recombination has caused occasional mtDNA re-assortment. These findings implicate functional
mtDNA as a driver of CTVT global metastatic spread, further highlighting the important role of
mtDNA in cancer evolution.
DOI: 10.7554/eLife.14552.001
Introduction
The canine transmissible venereal tumour (CTVT) is a transmissible cancer that is contagious between
dogs via the transfer of living cancer cells during coitus. The disease usually manifests as localised
tumours involving the genital mucosa in both male and female domestic dogs. CTVT first arose from
the somatic cells of an individual dog that lived approximately 11,000 years ago; it subsequently sur-
vived beyond the death of this original animal by metastasising to new hosts (Murgia et al., 2006;
Rebbeck et al., 2009; Murchison et al., 2014; Decker et al., 2015). CTVT is found in dog popula-
tions worldwide, and is the oldest and most prolific cancer lineage known in nature
(Murchison et al., 2014; Strakova and Murchison, 2014; Strakova and Murchison, 2015). The
clonal evolution of CTVT renders this lineage a unique genetic tag with which to trace historical
global dispersals of dogs together with their human companions. Furthermore, the extreme longev-
ity of this lineage, its serial colonisation of genetically distinct allogeneic hosts and its occasional
uptake of host mitochondrial DNA (mtDNA) by horizontal transfer (Rebbeck et al., 2011), provide
opportunities to probe genetic vulnerabilities in cancer and to identify novel host-tumour interac-
tions. We analysed 449 complete mtDNAs in CTVT and used these to investigate the frequency and
timing of mtDNA horizontal transfer in this lineage; furthermore, we assessed the contribution of
selection to CTVT mtDNA evolution and searched for evidence of mtDNA recombination.
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Results and discussion
To investigate the global CTVT population structure and estimate the frequency and timing of
mtDNA horizontal transfer, we performed low-coverage whole genome sequencing ( ~ 0.3X whole
genome coverage) on 449 CTVT tumours and 338 matched hosts collected from 39 countries across
six continents (Materials and methods) (Figure 1—figure supplement 1, Supplementary file 1).
MtDNA was sequenced at ~70X coverage, indicating that each CTVT cell carries approximately 470
mtDNA copies (Figure 1—figure supplement 2, Supplementary file 2, Materials and methods).
CTVT was confirmed by identification of a characteristic rearrangement involving a long interspersed
nuclear element (LINE) near the MYC locus (Katzir et al., 1985; 1987) (Supplementary file 3).
We identified 1005 single point substitution variants and 27 short insertions and deletions (indels)
in the CTVT mtDNA population (Supplementary files 4, 5, 6, 7, 12, 13). CTVT mtDNA somatic sub-
stitution mutations (see Materials and methods) had the characteristic profile that is observed in
human cancers, dominated by C>T and T>C mutations showing a striking strand bias (Ju et al.,
2014) (Figure 2—figure supplement 1). This mutational process is probably replication-coupled,
and mutations associated with this process appear to accumulate at a roughly constant rate in
human cancers (Ju et al., 2014). A maximum likelihood phylogenetic tree constructed with mtDNA
sequences from CTVT, matched hosts and 252 additional dogs (see Supplementary file 8) revealed
that CTVT mtDNAs cluster in five distinct groups within dog mtDNA haplogroup A1 (Figure 1A, Fig-
ure 1—figure supplement 3, Figure 1—source data 1). These data suggest that CTVT mtDNAs
have at least five independent origins, demarcating five groups that we have named CTVT clades 1
to 5.
Although CTVT originated about 11,000 years ago, whole genome sequences of two CTVT
tumours derived from clades 1 and 2 indicated that these two clades shared a common ancestor
eLife digest A unique cancer called canine transmissible venereal tumour (CTVT) causes ugly
tumours to form on the genitals of dogs. Unlike most other cancers, CTVT is contagious: the cancer
cells can be directly transferred from one dog to another when they mate. The disease originated
from the cancer cells of one individual dog that lived approximately 11,000 years ago. CTVT now
affects dogs all over the world, which makes it the oldest and most widespread cancer known in
nature.
Like healthy cells, cancer cells contain compartments known as mitochondria that produce the
chemical energy needed to power vital processes. Inside the mitochondria, there is some DNA that
encodes the proteins that mitochondria need to perform this role. Changes (or mutations) to this
mitochondrial DNA (mtDNA) may stop the mitochondria from working properly. CTVT cells have
previously been found to occasionally capture mtDNA from normal dog cells, which suggests that
replenishing their mtDNA may help promote CTVT cell growth. Furthermore, these captured
mtDNAs act as genetic "flags" that can help trace the spread of the disease.
Here, Strakova, Nı́ Leathlobhair et al. analysed the mtDNA in CTVT tumours collected from over
400 dogs in 39 countries. The analysis shows that CTVT cells have captured mtDNA from normal
dog cells on at least five occasions. Over the last 2,000 years, the disease appears to have spread
rapidly around the world, perhaps transported by dogs travelling on ships along historic trade
routes. CTVT may have only reached the Americas within the last 500 years, possibly carried there
by dogs brought by Europeans. Likewise, CTVT probably only came to Australia after European
contact.
The experiments also revealed that the most damaging types of mutations were absent from the
mtDNA of CTVT, which suggests that fully functioning mitochondria play an important role in CTVT.
Unexpectedly, Strakova, Nı́ Leathlobhair et al. found evidence that certain sections of mtDNA in
some CTVT cells have been exchanged, or shuffled, with the mtDNA captured from normal dog
cells. This type of “recombination” is not usually thought to occur in mtDNA, and has not previously
been detected in cancer. Future studies will determine if this process is widespread in other types of
cancer, including in humans.
DOI: 10.7554/eLife.14552.002
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Figure 1. CTVT has acquired mtDNA by horizontal transfer at least five times. (A) Maximum likelihood phylogenetic tree constructed with complete
mtDNA sequences from 449 CTVT tumours and 590 dogs. Coloured and black dots represent CTVT and dog mtDNA respectively. Scale bar indicates
base substitutions per site. (B) Number of somatic substitution mutations per CTVT tumour. Coloured bars indicate somatic mutations acquired by each
tumour since mtDNA capture. Grey bars indicate substitutions absent from normal dog mtDNA haplotypes but common to all tumours within a clade;
thus the early somatic or rare germline status of these variants is unknown. (C) Geographical distribution of clades. Coloured dots represent locations
from which one or more CTVT tumours were collected. (D) Simplified representation of maximum likelihood phylogenetic trees for each clade. Trees
illustrate nodes with bootstrap support >60, and shaded triangles represent coalescence of individual branches within each group. Two tumours were
collected in the United States and the Netherlands respectively from dogs imported from Guatemala and Romania. Discontinuous grey lines represent
contributions of substitutions absent from normal dog mtDNA haplotypes but common to all tumours within a clade. Assuming a constant
accumulation of mutations within and between clades, approximate number of somatic mutations and estimated timing is shown. Maximum likelihood
trees upon which these representations are based are found in Figure 1—source data 2.
DOI: 10.7554/eLife.14552.003
The following source data and figure supplements are available for figure 1:
Source data 1. Maximum likelihood phylogenetic tree of CTVT mtDNA.
DOI: 10.7554/eLife.14552.004
Source data 2. Maximum likelihood phylogenetic trees for CTVT clades 1 to 5.
DOI: 10.7554/eLife.14552.005
Figure supplement 1. Geographical locations and mtDNA clades for CTVT tumours and hosts.
DOI: 10.7554/eLife.14552.006
Figure supplement 2. mtDNA copy number in CTVT.
DOI: 10.7554/eLife.14552.007
Figure supplement 3. CTVT mtDNA clades 1 to 5 all arose from dog mtDNA clade A.
DOI: 10.7554/eLife.14552.008
Figure supplement 4. Reconstructed donor haplotypes for CTVT mtDNA clades 1 to 5.
DOI: 10.7554/eLife.14552.009
Figure 1 continued on next page
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approximately 460 years ago (Murchison et al., 2014). We investigated the relative time since each
CTVT mtDNA horizontal transfer event by estimating the number of mtDNA somatic mutations
acquired by each clade since mtDNA capture (Figure 1B). This analysis revealed that clade 1 mtDNA
carry more than double the number of mtDNA somatic mutations (22.5 mutations average) com-
pared with clade 2 mtDNA (9.4 mutations average). By inferring that the clade 2 mtDNA horizontal
transfer event occurred no more than 460 years ago, this analysis suggests a maximum time since
mtDNA uptake of 1097 years for clade 1, 244 years for clade 3, 1690 years for clade 4 and 585 years
for clade 5, assuming a constant somatic accumulation of mutations in CTVT mtDNA
(Materials and methods). Importantly, two additional mutation rate estimates, derived using human
data (Ju et al., 2014), suggested similar timing for CTVT clade origins (Materials and methods,
Supplementary file 9). Thus, this analysis suggests that the original mtDNA, that was present in the
founder dog that first spawned CTVT, is not detectable in tumours that we have analysed, and indi-
cates that CTVT cells have captured mtDNA from transient hosts at least five times within the last
two thousand years.
The geographic distribution and phylogenies of the five CTVT clades reveal the dynamic
recent history of the CTVT lineage (Figure 1C, Figure 1D, Figure 1—figure supplement 1 and
Figure 1—source data 2). Clades 1 and 2, which occur most frequently in the CTVT population
that we analysed, both have a global distribution. Tumours that diverged early in the clade 1
lineage occur in Russia, Ukraine, China and India, suggesting an Old World origin for this clade
(Figure 1D). Clade 1 tumours in Central and South America share a single common ancestor that
probably existed no more than 511 years ago, suggesting introduction of CTVT to the Americas
with colonial contact; similarly, our data suggest a single introduction of CTVT to Australia after
European arrival (maximum 116 years ago) (Figure 1D, Supplementary file 9, see
Materials and methods). The distribution pattern and timing of clade 2 suggest that this clade
may have been transported between continents via trans-Atlantic and Indian Ocean trade routes
(Figure 1C and 1D). The more recent clade 3 lineage was found in Central and South America
and India, and the less frequent clades 4 and 5 occurred only in India and Nigeria respectively
(Figure 1C and 1D). The extensive and recent global expansion detected in the CTVT lineage is
consistent with signals of widespread admixture observed in worldwide populations of domestic
dogs (Shannon et al., 2015), highlighting the extent to which canine companions accompanied
human travellers on their global explorations.
Most somatic mutations in cancer are believed to be selectively neutral, and there is little evi-
dence in human cancers for negative selection operating to safeguard essential cellular processes
(Stratton et al., 2009). We searched for evidence of mtDNA functionality in CTVT cells by examin-
ing CTVT mtDNA for signals of negative selection. If present, negative selection would be
expected to operate on mtDNA to prevent homoplasmy of deleterious mutations. Consistent with
this prediction, the variant allele fraction (VAF) of nonsense substitutions and frameshift indels was
significantly lower than VAF for other substitutions and indels (Figure 2A and B, p=0.00019 and
p=3.03x10-05 respectively, two-sample Kolmogorov-Smirnov test). Furthermore, dN/dS for somatic
mtDNA mutations in CTVT showed significant deviation from neutrality both for nonsense (0.187,
p=1.02x10-07) and missense (0.748, p=4.18x10-03) mutations (Figure 2C). Together with evidence
of reduced VAF for truncating mtDNA mutations in human cancers (Ju et al., 2014;
Stewart et al., 2015), these findings provide evidence for the activity of negative selection operat-
ing to preserve mtDNA function in CTVT and indicate that, at least in some cancers, functional
mtDNA contributes to driving cancer.
MtDNA is usually assumed to be clonally inherited and recombinationally inert. However,
mtDNA recombination has been directly observed in various eukaryotes (Lunt and Hyman, 1997;
Hoarau et al., 2002; Ladoukakis and Zouros, 2001; Gantenbein et al., 2005; Ujvari et al., 2007;
Bergthorsson et al., 2003) and has been proposed as a mechanism for mtDNA repair
(Thyagarajan et al., 1996). Recombination of maternal and paternal mtDNA haplotypes has been
observed in rare cases of human biparental mtDNA inheritance (Kraytsberg et al., 2004;
Figure 1 continued
Figure supplement 5. Sequence contribution of nuclear-encoded mtDNA (NuMTs).
DOI: 10.7554/eLife.14552.010
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Zsurka et al., 2005), and mtDNA recombination activity is present in human cell extracts
(Thyagarajan et al., 1996). However, mtDNA recombination has not, to our knowledge, been pre-
viously detected in cancer. Given the possibility for coexistence of two distinct mtDNA haplotypes
in CTVT cells, we searched for evidence of mtDNA recombination in CTVT using recombination-
detection algorithms 3seq and SiScan (Boni et al., 2007; Gibbs et al., 2000). Remarkably, these
algorithms detected significant evidence for mtDNA recombination in CTVT clade 1, detecting
recombination breakpoints at around MT:5430 and MT:16176. Maximum likelihood phylogenetic
trees constructed using segments MT:1–5429 and MT:5430–16176 derived from clade 1 mtDNA
produced distinct topologies (Figure 3A, Figure 3—source data 1). Further inspection of clade 1
mtDNA haplotypes suggested that recombination replaced MT:1–5429 in a clade 1 mtDNA haplo-
type that diverged from Central American clade 1 CTVTs and that subsequently colonised areas of
South and Central America (Chile, Colombia, Ecuador, Panama, Paraguay) (Figure 3B).
These data provide evidence of an mtDNA recombination event in an ancestral CTVT lineage. We
searched for evidence of more recent mtDNA recombination by examining outliers on CTVT mtDNA
phylogenetic trees (Figure 1—source data 2, Supplementary file 10). This analysis identified 559T,
a CTVT tumour derived from a male dog in Nicaragua (Figure 3C). Further investigation of mtDNA
in 559T revealed what appeared to be a CTVT clade 1 mtDNA haplotype (CTVT_1B2b1_29) superim-
posed upon a dog mtDNA haplotype (A1d1a_1), neither of which resembled the mtDNA haplotype
found in normal tissues from this host dog, 559H (B1_1 haplotype). Phasing of mtDNA variants in
559T using long sequence reads indicated the presence of at least three distinct mtDNA haplotypes
in this tumour, each representing a recombination product apparently derived from mtDNA haplo-
types CTVT_1B2b1_29 and A1d1a_1 (Figure 3C). These data suggest that a tumour antecedent of
559T captured haplotype A1d1a_1 mtDNA from its host. Recombination was initiated between
mtDNA haplotypes CTVT_1B2b1_29 and A1d1a_1, and cells containing these recombination prod-
ucts were passed to host 559H. Alternatively it is possible that 559H received a mixture of both nor-
mal and CTVT cells from its CTVT donor animal, and mtDNA capture and recombination occurred
within 559H. It must also be mentioned that the A1d1a_1 haplotype resembles the CTVT clade 3
donor haplotype (Figure 1—figure supplement 4); thus we cannot exclude the possibility that the
Figure 2. Negative selection operates to prevent the accumulation of gene-disrupting mutations in CTVT. Cumulative distribution functions for variant
allele fraction (VAF) for gene-disrupting (A) substitutions and (B) indels. P-values were calculated using two-sample Kolmogorov-Smirnov tests. (C) dN/
dS for somatic nonsense and missense substitutions. P-values were calculated using a likelihood ratio test with parameters estimated using a Poisson
model. Error bars indicate 95 percent confidence intervals.
DOI: 10.7554/eLife.14552.011
The following figure supplement is available for figure 2:
Figure supplement 1. CTVT mtDNA somatic mutation spectrum.
DOI: 10.7554/eLife.14552.012
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recombination that we observe in 559T involved horizontal transfer between clade 1 and clade 3
CTVT tumours that occurred within the same animal.
Our analysis provides evidence for occasional mtDNA recombination activity in CTVT cells. The
mechanism whereby distinct mtDNA molecules are able to interact within the cell, and the nature of
the signals that trigger onset of mtDNA recombination are not clear. Further analysis will determine if
DNA damage signalling is involved, and it is interesting to observe that a truncating nonsense muta-
tion in COX3 was found in some 559T haplotypes (Figure 3C). Although we could not find evidence of
mtDNA recombination in CTVT beyond those described, we cannot exclude the possibility that







































Figure 3. Ancient and modern mtDNA recombination in CTVT. (A) Maximum likelihood phylogenetic trees constructed using segments MT:1–5429 and
MT:5430–16176 from clade 1 CTVT mtDNAs. Three clade 1 mtDNA haplotype groups are represented by coloured dog silhouettes, and their
geographical distributions are colour-coded on the map. Bootstrap values were calculated from 100 iterations. Maximum likelihood trees upon which
these representations are based are found in Figure 3—source data 1. (B) Simplified haplotype diagrams for clade 1 CTVT mtDNAs derived from
groups shown in (A). Germline variants were present in the donor mtDNA that founded clade 1, represented by the A1/A1c/A1e dog haplotype (see
Figure 1—figure supplement 4). Region putatively replaced by recombination is outlined with orange box. (C) Recombination detected in tumour
559T (Nicaragua). The estimated per cent contribution of each recombined haplotype to the mtDNA population within 559T CTVT cells is shown, and
grey arrows indicate likely sites of recombination.
DOI: 10.7554/eLife.14552.013
The following source data is available for figure 3:
Source data 1. Ancient mtDNA recombination in CTVT clade 1.
DOI: 10.7554/eLife.14552.014
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phylogenetic, mutation rate and selection analyses (Figure 1, 2) have been influenced by an unde-
tected recombination signal. However, the presence in all (non-recombining) CTVT mtDNAs of a set
of clade-specific markers (Figure 1—figure supplement 4), the absence (beyond 559T) of distinctive
phylogenetic outliers (Figure 1—source data 2), the very low frequency of back-mutation
(Supplementary file 10), the strong somatic signal identified in the CTVT mtDNA mutational spec-
trum (Figure 2—figure supplement 1), and the failure of recombination-detection algorithms to
detect further recombination, suggest that, if such a signal is present, it is at a low level.
CTVT is the world’s oldest known cancer whose metastatic spread through its global host popula-
tion provides unique insights into evolutionary processes operating in cancer. Our analysis of CTVT
mtDNA has illuminated five mtDNA horizontal transfer events which trace two millennia of CTVT
global spread. Negative selection has operated on CTVT to maintain mtDNA integrity at the level of
nonsense and missense mutations, and occasional mtDNA recombination has occurred, possibly to
repair damaged mtDNA. Evidence of negative selection demonstrates that maintenance of functional
mtDNA is important for the biology of CTVT; and the observation of multiple mtDNA horizontal trans-
fer events further supports the possibility that mtDNA capture from hosts is a positively selected adap-
tive mechanism (Rebbeck et al., 2011; Tan et al., 2015; Spees et al., 2006). This study highlights the
important role of functional mtDNA in cancer and reveals unexpected biological mechanisms that
have operated in an ancient mammalian somatic cell lineage.
Materials and methods
Sample collection and DNA extraction
This study was approved by the Department of Veterinary Medicine, University of Cambridge, Ethics
and Welfare Committee (reference number CR174). Tumour and host (gonad, skin, blood or liver)
tissue samples were collected into RNAlater solution and stored at 4˚C until processing. Genomic
DNA was extracted using the Qiagen DNeasy Blood and Tissue extraction kit. Sample information is
presented in Supplementary file 1.
Confirmation of canine transmissible venereal tumour (CTVT) diagnosis
Quantitative PCR (qPCR) assays were performed to confirm CTVT diagnosis (Supplementary file
3) by detection of the CTVT-specific LINE-MYC genomic rearrangement (Murgia et al., 2006;
Rebbeck et al., 2009; Murchison et al., 2014; Katzir et al., 1985; 1987). Each qPCR was per-
formed in triplicate with SYBR Select Master Mix (Life Technologies, Carlsbad, CA) using an
Applied Biosystems 7900HT Fast Real-Time PCR system instrument (Applied Biosystems, Foster
City, CA) with conditions and primers specified below.
Primer Sequence
LINE-MYC
primers (obtained from [Rebbeck, 2007])
Forward AGG GTT TCC CAT CCT TTA ACA TT
Reverse AGA TAA GAA GCT TTT GCA CAG CAA
ACTB primers Forward CTC CAT CAT GAA GTG TGA CGT TG
Reverse CGA TGA TCT TGA TCT TCA TTG TGC
qPCR master mix reagents Volume per reaction (ml)
SYBR Green Mix 10
Primers (5 mM/primer) 2.4
DNA (20 ng/ml) 0.5
Water 7.1
Total volume 20
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Stage of qPCR amplification Temperature (˚C) Time (s)
Initial denaturation 95 600
40 cycles 95 15
60 60
Final dissociation 95 15
Standard curves were constructed for each primer set using CTVT tumour 29T1 as reference. Rel-
ative DNA input was calculated using standard curves as follows: (Ct = m(log10(iA)) + b), with each
of the parameters defined as follows: Ct = threshold cycle, m = slope of the standard curve, iA =
input amount, b = y-intercept of the standard curve. Relative DNA input for LINE-MYC was then nor-
malised to ACTB. LINE-MYC and ACTB are present in three and two copies respectively in 24T and
79T CTVT tumours (Murchison et al., 2014); however, it is possible that copy number at these loci
differs between tumours in the current dataset.
DNA sequencing
Whole genome sequencing libraries with insert size 100 to 400 base pairs (bp) were constructed using
standard methods according to manufacturer’s instructions and sequenced with 75bp paired end
reads on an Illumina HiSeq2000 instrument (Illumina, San Diego, CA) to an average whole genome
depth of 0.3X; average mitochondrial DNA (mtDNA) coverage was ~70X. Reads were aligned with
the CanFam3.1 dog reference genome (Lindblad-Toh et al., 2005) (http://www.ensembl.org/Canis_
familiaris/Info/Index) using the BWA alignment tool (Li and Durbin, 2009). To calculate the mitochon-
drial copy number, we used the following equation: (mtCOV/nuclCOV)*P, where mtCOV = average
coverage across the mitochondria, nuclCOV = average coverage across the nuclear genome and P =
ploidy. The ploidy used in our calculations was 2 for both CTVT tumours and CTVT hosts
(Murchison et al., 2014). Host and tumour samples with average MT coverage >300X were excluded
from the copy number calculations (see Supplementary file 2A).
Samples 1380T and 1381T were sequenced separately, based on the methods described in Pang
et al (Pang et al., 2009). Complete mitochondrial genomes were amplified using the primers listed in
Pang et al (Pang et al., 2009) with a number of additional primers listed below. The PCR conditions
are specified below.
PCR master mix reagents Volume per reaction (ml)
1 X PCR LATaq buffer 2.5
Primer forward and reverse (10 mM) 1.2 (each)
DNA (100-200 ng/ml) 1.2
LATaq DNA polymerase 0.25
1X dNTP (10 mM) 4
Water 14.65
Total volume 25
Stage of PCR amplification Temperature (˚C) Time (s)
Initial denaturation 94 300
12 cycles (touchdown PCR program, reduce 1˚C each cycle) 94 60
61–50 60
74 90
Continued on next page
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Continued
Stage of PCR amplification Temperature (˚C) Time (s)
25 cycles 94 60
52 60
74 90
Final extension 74 420
Primer name Sequence (5’–3’)
D0132 ACC GTA AGG GAA TGA TGA A
D0136 TGT AAG TGG TCG TAG AGG TTC
D0141 AGG CGG ACT AAA TCA AAC TCA
D0146 GGG GTA TCT AAT CCC AGT TT
D0149 AAG TTT GGT AGC ACG AAG AT
The PCR products were purified using a 1.0% agarose gel and sequenced on a 3730xl DNA analy-
ser (Applied Biosystems) with a Big Dye Terminator v3.1 Sequencing Kit (Applied Biosystems). The
sequenced fragments were assembled by Seqman (DNASTAR, Madison, WI) and the complete mito-
chondrial genomes were aligned with the CanFam3.1 dog mitochondrial reference genome (Lind-
blad-Toh et al., 2005).
Nuclear copies of mtDNA (NuMT) analysis
Nuclear copies of mtDNA (NuMTs) are mtDNA fragments that have been incorporated into the
nuclear genome. Over 150 NuMTs have been identified in the canine genome (Verscheure et al.,
2015). Somatically acquired NuMTs have also been described in human cancer (Ju et al., 2015).
Given that our study design did not involve purification of cytoplasmic mtDNA genomes, we
assessed the possibility that our mtDNA variant analysis has been influenced by NuMTs.
NuMTs in CanFam3.1
We first assessed the potential contribution of NuMTs present within the CanFam3.1 assembly to
our variant calling. We used wgsim (https://github.com/lh3/wgsim) to simulate sequence reads from
CanFam3.1 (excluding the MT chromosome) to a coverage of 0.3X (i.e. the average nuclear genome
coverage sequenced as part of this study). We then used BWA (Li and Durbin, 2009) to align the
reads to the CanFam3.1 MT reference and used Samtools depth (Li et al., 2009; Li, 2011) to assess
the MT genome coverage. Any MT genome coverage detected from this analysis would be
expected to arise from NuMTs. The average MT genome coverage from this analysis was 0 (Fig-
ure 1—figure supplement 5), indicating that the NuMTs known to be present within CanFam3.1 are
at insufficient copy number and/or are too divergent to map to the MT reference genome using the
alignment parameters used in this study.
Somatically acquired NuMTs
The analysis described above confirms that NuMTs that form part of the CanFam3.1 assembly have
not impacted on the variant analysis performed in this study. However, it is possible that somatically
acquired NuMTs that are not captured in the CanFam3.1 assembly could confound our variant
analysis.
The following observations argue against the possibility that NuMT-derived variants have had a
significant impact on our tumour variant calling:
. As CTVT is a clonal lineage, somatically acquired NuMT-derived variants would be expected
to present as stable low-VAF variants across all tumours within a phylogenetic group. Variants
with these features were not observed.
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. The mutation spectrum that we observed in CTVT mtDNA has the distinctive profile character-
istic of the known somatic mtDNA mutational process (Figure 2—figure supplement 1 and
Ju et al., 2014). As this mutational process is specific to cytoplasmic mtDNA, this observation
suggests that the majority of variants within our set are of cytoplasmic origin.
Substitution calling
Extraction and filtering
Substitutions were called using CaVEMan (Cancer Variants through Expectation Maximisation), an in-
house variant calling algorithm, as previously described (Nik-Zainal et al., 2012) (http://cancerit.
github.io/CaVEMan/). As CaVEMan is designed for matched tumour-normal data, and CTVT tumours
and normals are unmatched (i.e. they are different individuals), we used simulated reads derived
from the reference genome as the ’normal’, and called all substitution variants relative to this. A vari-
ant allele fraction (VAF value, i.e. number of reads supporting the substitution variant as a fraction of
the total number of reads covering the substitution variant position) was reported for each substitu-
tion detected. The following list of in-built post-processing filters was used to improve the specificity
and sensitivity of substitution calls:
. At least one third of mutant alleles must have base quality >25.
. Mean mapping quality of reads supporting a substitution variant call must be 21.
. Substitution variant calls supported only by the first or last 15bp of reads were discarded.
. Substitution variants were discarded if they occurred 10bp upstream or downstream of an
unfiltered indel called in the same sample (as detected by the indel-detecting algorithm
cgpPindel see ’Indel calling-Extraction and filtering’). The 10bp range was extended by the
REP value for samples where an indel had been called with REP>0; REP represents the number
of times the inserted/deleted base(s) occurs in the sequence directly 5’ or 3’ of the putative
indel.
. Substitution variant calls were discarded if they occurred within region MT:16129-16430 inclu-
sive; this is a simple repeat region as defined by the UCSC (http://genome.ucsc.edu/) table
browser (Dog, CanFam3.1).
. If the reference allele was supported by at least one read on both strands (forward and
reverse), then we required that the mutant allele should be supported by at least one read on
both strands.
Substitutions in 1380T and 1381T were called using MEGA (Molecular Evolutionary Genetics Anal-
ysis) (Tamura et al., 2013).
Post processing
Somatic substitutions in tumours with matched hosts
To remove tumour substitutions caused by host contamination, substitutions that were called in
both tumour and matched host, but had VAF<0.9 in the tumour, were discarded. Substitutions with
VAF>0.9 in both tumour and matched host were considered to be likely germline substitutions
shared between host and tumour, and were retained. Low coverage hosts (defined as average cover-
age <20X, Supplementary file 2A) were additionally checked for evidence of substitutions at posi-
tions where substitutions were called in the corresponding tumour, and the substitution was
discarded in the tumour if at least one read supporting the substitution was found in the low cover-
age host. All tumour substitutions with VAF<0.5 were discarded if the matched host was of low cov-
erage. Low-level tumour-contaminated hosts were additionally checked for the presence of
substitutions identified in other tumours (see Supplementary file 4A) and any substitutions arising
due to contamination were discarded.
Somatic substitutions in tumours without matched hosts
VAF value was used to identify substitutions likely arising due to host contamination in tumours for
which matched hosts were not available (see Supplementary file 1 for tumours without matched
hosts). We used VAF plots, which display VAF value versus genomic position, to identify the level of
host contamination in each tumour. We then discarded any substitution below a VAF cutoff, speci-
fied uniquely for each tumour based on its estimated level of host contamination (for most tumours,
the VAF cutoff was 0.5 or 0.6). If VAF plots did not show clear distinctions between tumour
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substitutions and host contamination (i.e. host contamination was greater than~ 40%; this category
included 9 tumours), we identified likely tumour substitutions as those which were present in phylo-
genetically-related tumours. Remaining substitutions were removed if they were also found in normal
dogs (see ’CTVT host and published dog genome germline substitutions list’, Supplementary file
4F); those substitutions that were not found either in phylogenetically-related tumours or in normal
dogs were kept as putative somatic substitutions (total of 11 substitutions).
Germline substitutions in hosts
Substitutions in hosts were filtered using filters described in ’Substitution calling-Extraction and fil-
tering’. Low coverage hosts (defined as average coverage <20X, Supplementary file 2A) were fur-
ther checked for evidence of substitutions at positions where a substitution was called in the
corresponding tumour as described in ’Somatic substitutions in tumours with matched hosts’.
Caution should be taken when considering substitution lists for low coverage hosts and hosts
with regions of low coverage (see Supplementary file 2A for average coverage per sample and
Supplementary file 2B for list of samples with low coverage mtDNA regions), as these may contain
false negatives due to low coverage.
Additional quality checks and validation
Additional quality filtering was performed in low coverage regions, regions with low-mapping qual-
ity, and regions containing variable-length polyC homopolymer tracts (Fregel et al., 2015). Substitu-
tions that were subsequently completely excluded from the analysis as a part of this check are listed
in the table below.
Position Base change Justification for excluding substitution
15493 G>A Inconsistently called due to low coverage and decreased mapping quality in this region
15505 T>C Inconsistently called due to low coverage and decreased mapping quality in this region
15632 C>T Frequently miscalled due to decreased mapping quality in this region
15639 T>A Frequently miscalled due to decreased mapping quality in this region
15639 T>G Frequently miscalled due to decreased mapping quality in this region
15931 A>G Frequently miscalled due to its presence in the same position as a frequently miscalled indel (middle of a
homopolymer tract)
16672 C>T Frequently miscalled due to its proximity to a frequently miscalled indel (associated with a very long homopolymer
tract)
16705 C>T Frequently miscalled due to low coverage in this region
Substitutions that were discarded due to proximity to an indel (see ’Substitution calling-Extraction
and filtering’ above) were visually inspected in Integrative Genomics Viewer (IGV) (Robinson et al.,
2011; Thorvaldsdottir et al., 2013). A subset of these substitutions had substantial support and
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Host contamination levels in each tumour were estimated from VAF plots (see ’Somatic substitutions
in tumours without matched hosts’ above). Substitutions that were present in tumours but not in
matched host were identified, and their average VAF used to estimate the proportion of tumour
mtDNA (see Supplementary file 2C for estimated tumour cell fraction in each tumour). Substitution
VAFs were normalised to take account of host contamination in Figure 2A and Supplementary files
4B,C. Tumour variants with normalised VAF<1 most likely represent heteroplasmic variants; how-
ever, we cannot exclude that these represent cellular subclones harbouring distinct homoplasmic
mtDNA populations.
Recurrent mutations and back mutations
Back mutations and recurrent mutations occurring in tumours were identified by inspecting positions
of tumours carrying each substitution on phylogenetic trees (Figure 1—source data 2).
Predicted functional consequences of substitutions
Variant effect predictor (VEP) (McLaren et al., 2010) was used to predict the functional consequen-
ces of single point substitutions, as annotated in Supplementary file 6.
Extracting substitution variants from publicly available dog sequences
In order to enrich our panel of germline substitutions created from 338 CTVT hosts, we included
an additional set of 252 publicly available complete dog mtDNA genomes (see
Supplementary file 8). To extract substitution variants from available fasta files, sequences were
aligned with the CanFam3.1 dog mitochondrial reference genome using Clustal Omega
(Sievers et al., 2011). Alignment errors in the multiple sequence alignment, usually due to mis-
calls caused by closely mapped indels, were inspected manually and corrected to minimise gaps.
Substitutions were extracted using snp-sites (https://github.com/sanger-pathogens/snp_sites). For
those samples missing data in regions MT: 15510–15532 and MT: 16040–16550 we substituted
the most likely substitution at polymorphic sites based on phylogenetic position. Our filtering
rules were applied to the substitution set where applicable (see ’Substitution calling-Extraction
and filtering’ and ’Additional quality checks and validation’) and substitutions called before MT
position 48 or after MT position 16671 were excluded due to low coverage in these regions in
our sequencing data. Substitutions represented by International Union of Pure and Applied
Chemistry (IUPAC) codes R, Y, S, W, K or M where one of the two possible calls was the same
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as the reference were changed to the base which was different to the reference. In cases where
the IUPAC code represented >2 bases (B, D, H, V, or N), the reference base was substituted.
Indel calling
Extraction and filtering
Small insertions and deletions (indels) were extracted from the sequencing data using cgpPindel
(https://github.com/cancerit/cgpPindel). The following list of in-built filters was used to improve the
specificity and sensitivity of indel calls:
. Indels were required to have 3 supporting reads on either the forward or reverse strands or
2 supporting reads on both the forward and reverse strands
. Indel calls with at least 4 supporting pindel-mapped reads were required to have at least 1
supporting BWA-mapped read or, failing that, if REP= 0 (see ’Substitution calling-Extraction
and filtering’), then at least one supporting pindel-mapped read on both strands.
. Indels called within the simple repeat region MT:16129–16430 inclusive were excluded.
Samples with very high coverage of the mitochondrial genome (24T-Dog, 24H-Dog, 1T-Dog, 2T-
Dog, 3T-Dog, 4T-Dog, 4H-Dog, 498H-Dog, 432T-Dog, 455T1-Dog, 231T-Dog, 79H-Dog, 79T-Dog),
see Supplementary file 2A, were excluded from this analysis due to frequent false positives,
together with samples 1380T-Dog and 1381T-Dog.
Post processing
Somatic indels
Indels called in tumours that were also called in at least one host were discarded as possibly arising
due to host contamination. Indels that were uniquely called in tumours without matched hosts were
discarded, as we could not rule out the possibility that they were caused by host contamination. All
remaining indels were visually validated using IGV (Robinson et al., 2011; Thorvaldsdottir et al.,
2013). The indels listed in the table below were discarded from the analysis as miscalls. In total 27
somatic indels were included in the analysis (see Supplementary file 5A).
Position Indel Sample Justification for discarding indel
9891 TGATTTATCTCATAATTATCA>
TATCTCATAATTATCATG
324T2-Dog Indel miscalled due to close proximity of two other indels in the same sample
9910 C>CAT 401T-Dog Indel miscalled due to presence of a substitution at the same position
Germline indels
The indels found on the host variant lists (Supplementary files 5B and 7B, Supplementary file 13)
include only those which were considered homoplasmic (VAF0.9) and which passed a visual valida-
tion performed using IGV (Robinson et al., 2011; Thorvaldsdottir et al., 2013).
Recurrent indels
Recurrent indels occurring in tumours were identified by inspecting phylogenetic positions of
tumours carrying each indel (Figure 1—source data 2).
Variant Allele Fraction calculation for indels
Although primary indel calling was carried out using cgpPindel, indel allele fraction for wild type and
mutant indels was calculated using vcfCommons (unpublished in-house software developed at the
Wellcome Trust Sanger Institute; for additional information please contact cgp@sanger.ac.uk). The
algorithm takes all mapped and unmapped reads in the region of an indel and performs an align-
ment of the reference and the predicted mutated path using Exonerate (Slater and Birney, 2005).
The predicted mutated path is the reference with the change predicted by cgpPindel applied to it.
Based on this alignment, reads are classified into 3 categories:
1. aligns to reference path
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2. aligns to mutated path
3. ambiguous; a read sequence aligns to the reference and mutated path with identical scores
which makes it impossible to determine the true path
Indel VAF values were normalised to take account of host contamination in Figure 2B.
Predicted functional consequences of indels
Variant effect predictor (VEP) (McLaren et al., 2010) was used to predict the functional effects of
indels, as listed in Supplementary file 7.
Phylogenetic analyses
Phylogenetic trees
Phylogenetic trees were constructed using a maximum likelihood (ML) method implemented in
PhyML 3.0 (Guindon et al., 2010) using the General Time Reversible (GTR) + G + I nucleotide substi-
tution model with transition/transversion (ts/tv) ratio, gamma distribution shape parameter and pro-
portion of invariant sites estimated in PhyML for each dataset. Phylogenetic trees constructed using
RAxML 8.2.6 with a rapid climbing algorithm and identical model specification were consistent with
the phylogenetic trees obtained using PhyML. Prior to tree construction jModelTest2 (Darriba et al.,
2012) (https://code.google.com/p/jmodeltest2) was used to determine the best fitting substitution
model for the alignment, inferred using the Akaike Information Criteria (AIC). The tree topology was
estimated using a combination of Nearest Neighbor Interchange (NNI) and Subtree Pruning and
Regrafting (SPR) (Hordijk and Gascuel, 2005) algorithms. Trees were visualised using Dendrocope
(Huson and Scornavacca, 2012). Bootstrap support values were obtained from 100 bootstrap repli-
cates. Nodes with 60% support are labelled in Figure 1—source data 2 and Figure 3—source
data 1. The long branch-lengths in CTVT clade 4 were further investigated by visually validating
sequence alignments involving these samples.
Confirmation of individual horizontal transfer events
Classification of tumour substitutions
CTVT tumour substitutions were classified as follows:
1) Tumour germline clade-defining substitutions (see Supplementary file 4D for the full list)
. Inferred to be present on the donor mtDNA haplotype which founded each of the five horizon-
tal transfer events
. Present within the pool of substitutions in the current dog population (see Supplementary file
4F)
. Shared by all tumours within each clade derived from the original CTVT cell which received the
horizontally transferred donated mtDNA (see Figure 1—figure supplement 4)
2) Tumour somatic substitutions (see Supplementary file 4B for the full list)
. Inferred to have arisen after the clade-defining horizontal transfer event
. Variable and phylogenetically informative within the set of tumours in one clade
. Any substitutions which were associated with inferred recombination event (present uniquely)
in 559T were discarded (see ’Mitochondrial recombination analysis’)
3) Tumour somatic substitutions - conservative list (see Supplementary file 4C for the full list)
. Inferred to have arisen after the clade-defining horizontal transfer event
. Variable and phylogenetically informative within the set of tumours in one clade
. Any substitutions which were classed as somatic but had the potential to be germline were
excluded from this list. Exclusions were based on:
& Inferred recombination events
& Occurrence in clade 3; clade 3 tumours carry very few somatic mutations, and so the pos-
sibility that clade 3 tumours arose from several independent mtDNA horizontal transfer
events cannot be excluded
& Occurrence on ancestral trunks; these include trunks defining CTVT_1A, CTVT_1B1,
CTVT_2A haplogroups; due to their ancestral divergence, it cannot be excluded that
these haplotypes are derived from independent mtDNA horizontal transfer events
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& Occurrence as a putative somatic mutation in tumours without hosts (see ’Somastic sub-
stitutions in tumours without matched hosts’)
. This list was used for the analysis in Figure 2A,C and Figure 2—figure supplement 1.
4) Tumour potential somatic substitutions (see Supplementary file 4E for the full list)
. Substitutions present within all tumours within one clade but not represented in the set of 590
normal dogs analysed as part of this study (Supplementary file 4F)
. It cannot be determined if these substitutions are germline substitutions which were present
on the mtDNA genome that founded each clade, or if they are early somatic substitutions that
occurred after the clade-defining horizontal transfer event, but prior to the divergence of
tumours analysed in our study.
Definition of a CTVT clade
A CTVT clade is defined as a group of tumours arising from an individual horizontal transfer event.
Each clade is defined with respect to the tumour substitution classification (see ’Classification of
tumour substitutions’) as follows:
1. CTVT tumours from the same clade cluster together on phylogenetic tree represented in
Figure 1A.
2. CTVT tumours from the same clade arose from a single donor mtDNA haplotype and therefore
share the same set of germline substitutions which was inferred to be originally present on the
donor mtDNA haplotype (germline clade-defining substitutions, see Figure 1—figure supple-
ment 4, ’Classification of tumour substitutions’).
3. The reconstructed donor mtDNA haplotype for each clade has a phylogenetically closely
related/identical haplotype in the current dog population (see Figure 1—figure supplement
4).
Estimated timing of clade divergence
Average number of somatic mutations (i.e. mutations arising after the horizontal transfer event) within
each clade was calculated for each of the five clades (see Supplementary file 9). For potential somatic
mutations (shown in grey in Figure 1B and D), we were unable to determine whether they occurred
before or after the horizontal transfer event, as they are present in all samples from the same clade,
but not in the pool of germline substitutions (see Supplementary file 4F). As the number of somatic
mutations influences the time of divergence, we included estimates both with and without potential
somatic mutations in our analysis (see Supplementary file 9). Presence of mitochondrial recombina-
tion in haplogroup CTVT_1B2b2 (clade 1) was taken into account when calculating the average num-
ber of mutations per clade (see ’Mitochondrial recombination analysis’). The timing of clade
divergence was estimated independently based on the following three methods, as explained below:
timing based on nuclear DNA (Murchison et al., 2014; Alexandrov et al., 2013), timing based on
number of cell divisions per homoplasmic mitochondrial mutation (Ju et al., 2014; Cohen and Steel,
1972), and timing based on number of mitochondrial mutations per year (Ju et al., 2014). All esti-
mates of CTVT dates assume a constant rate of accumulation of somatic mtDNAmutations both within
and between clades, including constant activity of selection (Figure 2).
Timing based on nuclear DNA
Based on the most recent common ancestor of samples 24T (CTVT clade 1) and 79T (CTVT clade
2) which is estimated to have existed approximately 460 years ago (Murchison et al., 2014), we
can assume that the maximum age of clade 2 (i.e. the more recent clade) is 460 years. Calibrated
according to this dating (Murchison et al., 2014; Alexandrov et al., 2013), and assuming a con-
stant rate of accumulation of mutations with time, the maximum number of CTVT somatic
mtDNA mutations per year is 0.0205 (calculated using average number of mutations in clade 2 =
9.437). The calculated maximum time since origin of clades 1, 3, 4 and 5, is shown in Figure 1D
and Supplementary file 9.
Timing based on number of cell divisions
A study of mtDNA mutations in human cancers estimated that one homoplasmic somatic mtDNA
mutation arises every ~1000 cell generations in human cancers (Ju et al., 2014). An experimental
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study estimated CTVT cell generation times to be 4 days for first stage tumours and >20 days for
second stage tumours (Cohen and Steel, 1972). Using 4 days and 20 days as a minimum and maxi-
mum generation time, and assuming a constant mtDNA somatic mutation rate in CTVT, we esti-
mated a minimum and maximum mutation rate of ~0.0183 and ~0.0913 mutations/year
respectively. See Supplementary file 9 for corresponding calculations of minimum and maximum
time since clade origins.
Timing based on number of mutations per year
A previous study correlated somatic mtDNA mutation accumulation in human cancers with
patient age (Ju et al., 2014). This suggested an approximate rate of ~ 0.025 mutations per year.
Assuming a similar rate in CTVT somatic mtDNA mutations and a constant CTVT somatic mtDNA




The host haplotype naming system was adapted from the cladistic canine mitochondrial DNA phy-
logeny nomenclature proposed by Fregel et al (Fregel et al., 2015). See Supplementary files 1 and
11 for all host haplotype names. Corresponding CTVT normal dog host samples were assigned into
one of the major clades (A, B, C, D, E and F). For subsequent levels, haplogroups were defined by
specific diagnostic variants, as defined by Fregel et al (Fregel et al., 2015). A unique number, fol-
lowing an underscore after the haplogroup name, distinguished distinct haplotypes within each hap-
logroup. Haplogroup-defining variants 15632 C>T, 15639 T>A and 15639 T>G were excluded from
our analysis (’Additional quality checks and validation’) and therefore we were unable to distinguish
between haplogroups A1c and A1e. Haplotypes which did not fit into any haplogroup were classi-
fied as ’unassigned’.
Tumour haplotypes
We devised a CTVT mtDNA haplotype naming system adapted from the cladistic canine mtDNA
phylogeny nomenclature proposed by Fregel et al (Fregel et al., 2015). See Supplementary file 1
and 11 for all CTVT tumour haplotype names. Each CTVT haplotype has a prefix ’CTVT_’, indicating
a tumour haplotype. Distinct CTVT clades are numbered (CTVT_1, CTVT_2, CTVT_3, CTVT_4 and
CTVT_5). For subsequent levels, hierarchical notation was used, where subsequent haplogroups
were named by alternating letters and numbers and the maximum number of levels included in the
hierarchical notation was five – i.e. 3 numbers and 2 letters (e.g. 1A1a1). The first letter is a Roman
capital; subsequently-used letters are lower case Roman letters. Any haplogroups beyond the maxi-
mum number of levels were considered as a single subgroup, in which individual haplotypes were
distinguished using a non-hierarchical numbering system - an underscore followed by a number (e.g.
1A1a1_1, 1A1a1_2, etc.). Underscores were only used to distinguish individual haplotypes after the
haplotype has been assigned to all 5 hierarchical levels (e.g. 1A_1 does not exist, as this haplotype
would be classified as 1A1 instead).
Reconstructed donor haplotypes
A ’donor haplotype’ was reconstructed for each of the clades, representing the inferred donor
mtDNA haplotype in each horizontal transfer event, and was used to root the trees for each clade in
Figure 1—source data 2. Donor haplotypes were reconstructed from the clade-defining germline
substitutions and the clade-defining potential somatic substitutions (see ’Classifications of tumour
substitutions’ above) and are shown in Figure 1—figure supplement 4. The phylogenetically closest
haplotype present in the current dog population is shown in the same figure.
Mitochondrial recombination analysis
Automated recombination analysis
The RDP4 package (Martin et al., 2015) was used to detect recombination events within the com-
plete sample set (i.e. 449 CTVT tumours, 338 CTVT hosts and 252 additional dogs) using a Bonfer-
roni corrected p-value cutoff of 0.05. Default parameters were used for the following programs
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implemented within the RDP package: RDP (Martin and Rybicki, 2000), MaxChi (Smith, 1992), Chi-
maera (Posada and Crandall, 2001), 3Seq (Boni et al., 2007) and SiScan (Gibbs et al., 2000).
Long read sequencing
A genomic library was created directly using 5mg of genomic DNA from sample 559T, not utilizing
shearing or amplification techniques, as previously described (Coupland et al., 2012). The library
was sequenced using two PacBio SMRT cells using the Pacific Biosciences RS sequencer (Pacific Bio-
sciences, Menlo Park, CA). Each SMRT cell yielded ~ 1Gb of sequence data with mean read length
11,421bp and N50 read length 19,382bp. Average sequence coverage across the mitochondrial
genome was 111.3X.
PacBio data analysis
PacBio sequence reads aligning to mtDNA were viewed in SMRT view (Pacific Biosciences) as well as
in Integrative Genomics Viewer (IGV) (Robinson et al., 2011; Thorvaldsdottir et al., 2013) and used
to phase the mitochondrial substitutions previously called in 559T (Nicaragua). The three most com-
mon recombinant haplotypes were completely phased, as shown in Figure 3C. Additional haplo-
types, which we were unable to phase completely and which were present at very low level (less
than 5%), were also identified. Reads derived from 559H, the host of 559T (haplotype B1_1), were
also identified. The reads used to phase the substitutions in the three most common haplotypes are
shown in the table below:
PacBio sequencing reads used for phasing of individual haplotypes







































The two strands of the mtDNA are known as the heavy and light strands, and the light strand is the
reference strand in CanFam3.1. Each mutation on the conservative somatic list (n=835, ’Classification
of tumour substitutions’, Supplementary file 4C) was classified as one of six possible substitutions in
the pyrimidine context (C>A, C>G, C>T, T>A, T>C, T>G) and assigned to a strand relative to the
reference (i.e. pyrimidine mutations (i.e. C>, T>) with respect to the reference were defined as light
strand mutations; purine mutations (i.e. A>, G>) with respect to the reference were defined as heavy
strand mutations). The immediate 5’ and 3’ sequence contexts for each CTVT mutation was
extracted from the dog mitochondrial reference genome for mutations on the heavy and light
strands, yielding a maximum of 96 mutation types (6 possible substitutions x 4 possible 5’ bases x 4
possible 3’ bases).
The number of observations of each substitution type was normalised to the triplet frequency
extracted from the canine mitochondrial genome. The following example illustrates how to calculate
the observed/expected ratio for T[C>T]G occurring on the heavy strand. We observed a total of 835
substitutions occurring across the MT genome; given that the TCG triplet is observed 117 times in
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the dog mitochondrial reference genome heavy strand, the frequency of TCG triplets occurring in
the dog mtDNA heavy strand is 117/16727 = 0.007, where 16,727 bp is the length of the dog mito-
chondrial genome. Using the frequency of TCG triplets in the reference genome, we can calculate
the expected number of T[C>T]G substitution types on the heavy strand as (total number of muta-
tions) x (TCG frequency on the heavy strand) / 3 (as there are 3 possible C>N substitutions) i.e.
expected number of T[C>T]G substitutions on the heavy strand = 835 x 0.007/ 3 » 1.95. As we
observed 22 T[C>T]G mutations on the heavy strand, the observed/expected ratio for this mutation
type was 22/1.95 = 11.28.
Triplets within region MT:16129–16430 inclusive (’Substitution calling-Extraction and filtering’), as
well as a set of specific excluded sites (’Additional quality checks and validation’) were excluded





Normalised VAF values for somatic substitutions were calculated as described in
’Host contamination’. Cumulative distribution functions for VAF scores (normalised to take into
account host contamination, see ’Host contamination’ above) were plotted for nonsense substitu-
tions (n = 10) and missense and synonymous substitutions (n = 610), using the conservative somatic
list (see ’Classification of tumour substitutions’ above and Supplementary file 4C). Statistical signifi-
cance was tested using the two-sample Kolmogorov-Smirnov test implemented in R
(R Development Core Team, 2013).
Indels
Normalised VAF for somatic indels was calculated as described in ’Predicted functional consequen-
ces on indels’. Cumulative distribution functions of normalised variant allele fractions were plotted
for frameshift (n = 18) and non-frameshift (n = 9) indels. Statistical significance was tested using the
two-sample Kolmogorov-Smirnov test implemented in R (R Development Core Team, 2013).
dN/dS
dN/dS was estimated using a method adapted from Martincorena et al. (2015). Briefly, a context-
dependent model with 192 substitution rates (12 possible substitution types C>A, C>G, C>T, T>A,
T>C, T>G, A>C, A>G, A>T, G>A, G>C, G>T x 4 possible 5’ bases x 4 possible 3’ bases) was used,
thus accounting for any confounding context-dependent effects. The substitution rate was modelled
as a Poisson process where the product of the underlying mutation rate and the impact of selection
give the rate. A likelihood ratio test was used to test the deviation from neutrality (wMIS=1 or
wNON=1), giving a p-value for the evidence of selection. To avoid any confounding effects due to
the highly strand-biased CTVT mtDNA mutation spectrum (Figure 2—figure supplement 1), we
excluded ND6, the only mitochondrially-encoded gene transcribed from the light strand, from this
analysis.
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Additional files
Supplementary files
. Supplementary file 1. Sample information. Summary of information available for 449 CTVT tumours
and 338 hosts sequenced in this study. Includes data on location, year of collection, CTVT mtDNA
clade, tumour and host mtDNA haplotypes, breed, age and sex.
DOI: 10.7554/eLife.14552.015
. Supplementary file 2. Sequencing coverage and tumour cell fraction. (A) Average per-base cover-
age for whole genome (CanFam3.1) and for mtDNA genome (CanFam3.1; NC_002008). (B) List of
11 CTVT hosts with low coverage mtDNA regions. (C) Estimated tumour cell fraction for 449 CTVT
tumours; tumour cell fraction was estimated by calculating the average VAF for variant substitutions
present in tumour but not in matched host for each tumour.
DOI: 10.7554/eLife.14552.016
. Supplementary file 3. Confirmation of CTVT diagnosis. Quantitative PCR (qPCR) was performed for
LINE-MYC, a CTVT-specific rearrangement (Katzir et al., 1985; Katzir et al., 1987). Each reaction was
performed in triplicate and a standard curve was used to detect relative DNA input at each locus.
’Normalised input’ represents the relative LINE-MYC input detected in each sample normalised to
ACTB (’Confirmation of canine transmissible venereal tumour (CTVT) diagnosis’,
Materials and methods). In general, we consider normalised input >0.05 as indicative of presence of
LINE-MYC. Sufficient DNA was not available for samples 1380T and 1381T; diagnosis in these cases
was performed with histopathology. *2T was grown as a xenograft.
DOI: 10.7554/eLife.14552.017
. Supplementary file 4. Single point substitution variant lists. (A) Total number of substitution variants
(n = 1005) identified in 449 CTVT tumours. (B) CTVT tumour somatic substitutions list (n = 928),
including the average VAF value normalised for host contamination (see Materials and methods
’Classification of tumour substitutions’). Back mutations are not included on the list. (C) CTVT tumour
conservative somatic substitutions list (n = 835), including the average VAF value normalised for host
contamination (see Materials and methods ’Classification of tumour substitutions’). Back mutations
are not included on the list. (D) Germline clade defining substitutions lists. Substitutions present in
the pool of host substitutions and also shared between all samples within a clade (see
Materials and methods ’Classification of tumour substitutions’). (E) Potential somatic substitutions
lists. Substitutions not present in the pool of host substitutions, but shared between all samples
within a clade (see Materials and methods ’Classification on tumour substitutions’). (F) Total number
of substitution variants (n = 1152) identified in 338 CTVT host samples and 252 publicly available
dog mitochondrial genomes (see Supplementary file 8).
DOI: 10.7554/eLife.14552.018
. Supplementary file 5. Summary of small insertions and deletions (indels). (A) Total number of inser-
tions and deletions identified in tumours (n = 27), including the average VAF value normalised for
host contamination (see Materials and methods) (B) Total number of homoplasmic insertions and
deletions in CTVT hosts (n = 7), including the average VAF value (see Materials and methods).
DOI: 10.7554/eLife.14552.019
. Supplementary file 6. Annotation of single point substitutions. Annotation of individual point sub-
stitution mutations in (A) 449 CTVT tumours (see list Supplementary file 4A, excluding back muta-
tions) and (B) 338 CTVT hosts (see list Supplementary file 4F). Annotation was performed using
Variant Effect Predictor (McLaren et al., 2010). In cases where a single substitution affects two differ-
ent genes, the two annotations are shown on different lines.
DOI: 10.7554/eLife.14552.020
. Supplementary file 7. Annotation of insertions and deletions (indels). Annotation of individual indels
(A) unique to CTVT tumours and (B) homoplasmic in CTVT hosts. Annotation was performed using
Variant Effect Predictor (McLaren et al., 2010).
DOI: 10.7554/eLife.14552.021
. Supplementary file 8. Publicly available mitochondrial dog genomes used in the study. Summary of
Genbank accession numbers and metadata for 252 publicly available dog mitochondrial genomes
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included in this study (see Materials and methods ’Extracting substitution variants from publicly avail-
able dog sequences’ and Supplementary file 4F).
DOI: 10.7554/eLife.14552.022
. Supplementary file 9. Timing analysis. Methods used to estimate the time since the origin of CTVT
clades 1 to 5. Potential somatic substitutions (see Materials and methods ’Classification of tumour
substitutions’ and Supplementary file 4E) are those which are shared between all tumours within a
clade, but that are not found in the normal dog population; thus we cannot confirm their germline
or early somatic status. The upper panel lists time estimates (years before present for the origin of
each clade) assuming potential somatic substitutions are somatic and arose after mtDNA horizontal
transfer; the lower panel lists time estimates (years before present for the origin of each clade)
assuming potential somatic substitutions are germline and were originally present on the mtDNA
haplotype that founded the clade.
DOI: 10.7554/eLife.14552.023
. Supplementary file 10. Summary of back mutations. List of back mutations attributable and non-
attributable to a putative recombination event.
DOI: 10.7554/eLife.14552.024
. Supplementary file 11. CTVT tumour and host mtDNA haplotype lists.
DOI: 10.7554/eLife.14552.025
. Supplementary file 12. Substitutions with corresponding VAF (before normalisation) for each of 449
CTVT tumours and 338 CTVT hosts. Supplementary file 12 is included as accompanying zip file.
DOI: 10.7554/eLife.14552.026
. Supplementary file 13. Indels with corresponding VAF (before normalisation) for each of 438 CTVT
tumours and 334 CTVT hosts. Samples with very high coverage of the mitochondrial genome were
excluded from the indel analysis (see Materials and methods ’Indel calling-Extraction and filtering’).
Supplementary file 13 is included as accompanying zip file.
DOI: 10.7554/eLife.14552.027
Major datasets
The following datasets were generated:
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Vilà C, Savolainen P, Maldonado JE, Amorim IR, Rice JE, Honeycutt RL, Crandall KA, Lundeberg J, Wayne RK.
1997. Multiple and ancient origins of the domestic dog. Science 276:1687–1689 . doi: 10.1126/science.276.
5319.1687
Zsurka G, Kraytsberg Y, Kudina T, Kornblum C, Elger CE, Khrapko K, Kunz WS. 2005. Recombination of
mitochondrial DNA in skeletal muscle of individuals with multiple mitochondrial DNA heteroplasmy. Nature
Genetics 37:873–877. doi: 10.1038/ng1606
Strakova et al. eLife 2016;5:e14552. DOI: 10.7554/eLife.14552 25 of 25
Short Report Cancer biology Genomics and evolutionary biology
